Novel Therapeutic Approaches and Targets for Treatment of Psoriasis

Giulia      Radi; Anna      Campanati; Federico      Diotallevi; Tommaso      Bianchelli; Annamaria      Offidani
Abstract

Background: Psoriasis is a multifactorial immune-mediated inflammatory disease, with a chronic relapsing-remitting course, which affects 2-3% of the worldwide population. Psoriasis involves skin, joints, or both, and it is associated with several comorbidities, including metabolic, rheumatological, cardiovascular, psychiatric complications, and other chronic inflammatory diseases, which are the expression of the complex underlying pathogenetic mechanism. An accurate characterization of the immune pathways involved in psoriasis led to recognize the new molecules, (IL)17 and 23, which become the new target of biologic therapy for moderate-to-severe plaque psoriasis.
Objective: The aim of this study is to collect data of literature about IL-17 and IL-23 inhibitors.
Methods: A descriptive review was conducted to identify the main data in the literature evaluating novel biologic treatments currently available: IL-17 inhibitors (secukinumab, ixekizumab and brodalumab) and IL-23 inhibitors (guselkumab, tildrakizumab and risankizumab).
Results: Dosing regimens, administration, efficacy, real-life efficacy and safety of IL-17 and IL-23 inhibitors are discussed in detail.
Conclusion: Currently approved novel biologic therapies for moderate to severe psoriasis revealed increasing effectiveness compared to previous biological therapy and a good safety profile.
Keywords: Psoriasis, ixekizumab, secukinumab, brodalumab, risankizumab, guselkumab, tidralkizumab.
Graphical Abstract

[1] 
Lebwohl, M. Psoriasis. Lancet,  2003, 361(9364), 1197-1204.
[http://dx.doi.org/10.1016/S0140-6736(03)12954-6 ] [PMID:  12686053] 
[2] 
Linder, D.; Altomare, G.; Amato, S.; Amerio, P.; Balato, N.; Campanati, A.; Conti, A.; Gisondi, P.; Prignano, F.; Saraceno, R.; Piaserico, S. PSOCUBE, a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidence-based algorithm. J. Eur. Acad. Dermatol. Venereol.,  2015, 29(7), 1310-1317.
[http://dx.doi.org/10.1111/jdv.12809 PMID: 25370415] 
[3] 
Ganzetti, G.; Campanati, A.; Offidani, A. Alopecia Areata: A possible extraintestinal manifestation of Crohn’s disease. J. Crohn’s Colitis,  2012, 6(9), 962-963.
[http://dx.doi.org/10.1016/j.crohns.2012.05.023 PMID: 22727660] 
[4] 
Bacchetti, T.; Campanati, A.; Ferretti, G.; Simonetti, O.; Liberati, G.; Offidani, A.M. Oxidative stress and psoriasis: The effect of antitumour necrosis factor-α inhibitor treatment. Br. J. Dermatol.,  2013, 168(5), 984-989.
[http://dx.doi.org/10.1111/bjd.12144 PMID: 23614561] 
[5] 
Campanati, A.; Ganzetti, G.; Di Sario, A.; Benedetti, A.; Offidani, A. Insulin resistance, serum insulin and HOMA-R. J. Gastroenterol.,  2013, 48(5), 673.
[http://dx.doi.org/10.1007/s00535-013-0769-2 PMID: 23478937] 
[6] 
Wollina, U.; Unger, L.; Heinig, B.; Kittner, T. Psoriatic arthritis. Dermatol. Ther.,  2010, 23(2), 123-136.
[http://dx.doi.org/10.1111/j.1529-8019.2010.01306.x ] [PMID:  20415819] 
[7] 
Yeung, H.; Takeshita, J.; Mehta, N.N.; Kimmel, S.E.; Ogdie, A.; Margolis, D.J.; Shin, D.B.; Attor, R.; Troxel, A.B.; Gelfand, J.M. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol.,  2013, 149(10), 1173-1179.
[http://dx.doi.org/10.1001/jamadermatol.2013.5015 ] [PMID:  23925466] 
[8] 
Gottlieb, S.L.; Gilleaudeau, P.; Johnson, R.; Estes, L.; Woodworth, T.G.; Gottlieb, A.B.; Krueger, J.G. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med.,  1995, 1(5), 442-447.
[http://dx.doi.org/10.1038/nm0595-442 PMID: 7585092] 
[9] 
Campanati, A.; Orciani, M.; Consales, V.; Lazzarini, R.; Ganzetti, G.; Di Benedetto, G.; Di Primio, R.; Offidani, A. Characterization and profiling of immunomodulatory genes in resident mesenchymal stem cells reflect the Th1-Th17/Th2 imbalance of psoriasis. Arch. Dermatol. Res.,  2014, 306(10), 915-920.
[http://dx.doi.org/10.1007/s00403-014-1493-3 PMID: 25160906] 
[10] 
Wagner, E.F.; Schonthaler, H.B.; Guinea-Viniegra, J.; Tschachler, E. Psoriasis: What we have learned from mouse models. Nat. Rev. Rheumatol.,  2010, 6(12), 704-714.
[http://dx.doi.org/10.1038/nrrheum.2010.157 PMID: 20877306] 
[11] 
Ellis, C.N.; Gorsulowsky, D.C.; Hamilton, T.A.; Billings, J.K.; Brown, M.D.; Headington, J.T.; Cooper, K.D.; Baadsgaard, O.; Duell, E.A.; Annesley, T.M. Cyclosporine improves psoriasis in a double-blind study. JAMA,  1986, 256(22), 3110-3116.
[http://dx.doi.org/10.1001/jama.1986.03380220076026 ] [PMID:  3023712] 
[12] 
Valdimarsson, H.; Bake, B.S.; Jónsdótdr, I.; Fry, L. Psoriasis: A disease of abnormal Keratinocyte proliferation induced by T lymphocytes. Immunol. Today,  1986, 7(9), 256-259.
[http://dx.doi.org/10.1016/0167-5699(86)90005-8 PMID: 25290627] 
[13] 
Abrams, J.R.; Lebwohl, M.G.; Guzzo, C.A.; Jegasothy, B.V.; Goldfarb, M.T.; Goffe, B.S.; Menter, A.; Lowe, N.J.; Krueger, G.; Brown, M.J.; Weiner, R.S.; Birkhofer, M.J.; Warner, G.L.; Berry, K.K.; Linsley, P.S.; Krueger, J.G.; Ochs, H.D.; Kelley, S.L.; Kang, S. CTLA4Ig-mediated blockade of T-cell costimulation in patients with Psoriasis vulgaris. J. Clin. Invest.,  1999, 103(9), 1243-1252.
[http://dx.doi.org/10.1172/JCI5857 PMID: 10225967] 
[14] 
Johnson-Huang, L.M.; Suárez-Fariñas, M.; Pierson, K.C.; Fuentes-Duculan, J.; Cueto, I.; Lentini, T.; Sullivan-Whalen, M.; Gilleaudeau, P.; Krueger, J.G.; Haider, A.S.; Lowes, M.A. A single intradermal injection of IFN-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin. J. Invest. Dermatol.,  2012, 132(4), 1177-1187.
[http://dx.doi.org/10.1038/jid.2011.458 PMID: 22277938] 
[15] 
Zaba, L.C.; Krueger, J.G.; Lowes, M.A. Resident and “inflammatory” dendritic cells in human skin. J. Invest. Dermatol.,  2009, 129(2), 302-308.
[http://dx.doi.org/10.1038/jid.2008.225 PMID: 18685620] 
[16] 
Chiricozzi, A.; Romanelli, P.; Volpe, E.; Borsellino, G.; Romanelli, M. Scanning the immunopathogenesis of psoriasis. Int. J. Mol. Sci.,  2018, 19(1), 19.
[http://dx.doi.org/10.3390/ijms19010179 PMID: 29316717] 
[17] 
Gutierrez, M.; De Angelis, R.; Bernardini, M.L.; Filippucci, E.; Goteri, G.; Brandozzi, G.; Lemme, G.; Campanati, A.; Grassi, W.; Offidani, A. Clinical, power Doppler sonography and histological assessment of the psoriatic plaque: Short-term monitoring in patients treated with etanercept. Br. J. Dermatol.,  2011, 164(1), 33-37.
[http://dx.doi.org/10.1111/j.1365-2133.2010.10026.x ] [PMID:  21070199] 
[18] 
Campanati, A.; Orciani, M.; Gorbi, S.; Regoli, F.; Di Primio, R.; Offidani, A. Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous s in psoriasis. Br. J. Dermatol.,  2012, 167(1), 68-76.
[http://dx.doi.org/10.1111/j.1365-2133.2012.10900.x PMID: 22356229] 
[19] 
Campanati, A.; Orciani, M.; Lazzarini, R.; Ganzetti, G.; Consales, V.; Sorgentoni, G.; Di Primio, R.; Offidani, A. TNF-α inhibitors reduce the pathological Th1 -Th17/Th2 imbalance in cutaneous mesenchymal stem cells of psoriasis patients. Exp. Dermatol.,  2017, 26(4), 319-324.
[http://dx.doi.org/10.1111/exd.13139 PMID: 27376466] 
[20] 
Campanati, A.; Orciani, M.; Ganzetti, G.; Consales, V.; Di Primio, R.; Offidani, A. The effect of etanercept on vascular endothelial growth factor production by cutaneous mesenchymal stem cells from patients with psoriasis. J. Int. Med. Res.,  2016, 44(1)(Suppl.), 6-9.
[http://dx.doi.org/10.1177/0300060515593229 PMID: 27683131] 
[21] 
Campanati, A.; Goteri, G.; Simonetti, O.; Ganzetti, G.; Giuliodori, K.; Stramazzotti, D.; Morichetti, D.; Bernardini, M.L.; Mannello, B.; Fabris, G.; Offidani, A. CTACK/CCL27 expression in psoriatic skin and its modification after administration of etanercept. Br. J. Dermatol.,  2007, 157(6), 1155-1160.
[http://dx.doi.org/10.1111/j.1365-2133.2007.08200.x ] [PMID:  17916208] 
[22] 
Aggarwal, S.; Ghilardi, N.; Xie, M.H.W.; de Sauvage, F.J.; Gurney, A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem.,  2003, 278(3), 1910-1914.
[http://dx.doi.org/10.1074/jbc.M207577200 PMID: 12417590] 
[23] 
Cua, D.J.; Sherlock, J.; Chen, Y.; Murphy, C.A.; Joyce, B.; Seymour, B.; Lucian, L.; To, W.; Kwan, S.; Churakova, T.; Zurawski, S.; Wiekowski, M.; Lira, S.A.; Gorman, D.; Kastelein, R.A.; Sedgwick, J.D. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature,  2003, 421(6924), 744-748.
[http://dx.doi.org/10.1038/nature01355 PMID: 12610626] 
[24] 
Hawkes, J.E.; Yan, B.Y.; Chan, T.C.; Krueger, J.G. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J. Immunol.,  2018, 201(6), 1605-1613.
[http://dx.doi.org/10.4049/jimmunol.1800013 PMID: 30181299] 
[25] 
Cho, M.L.; Kang, J.W.; Moon, Y.M.; Nam, H.J.; Jhun, J.Y.; Heo, S.B.; Jin, H.T.; Min, S.Y.; Ju, J.H.; Park, K.S.; Cho, Y.G.; Yoon, C.H.; Park, S.H.; Sung, Y.C.; Kim, H.Y. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J. Immunol.,  2006, 176(9), 5652-5661.
[http://dx.doi.org/10.4049/jimmunol.176.9.5652 PMID: 16622035] 
[26] 
McGeachy, M.J.; Bak-Jensen, K.S.; Chen, Y.; Tato, C.M.; Blumenschein, W.; McClanahan, T.; Cua, D.J. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol.,  2007, 8(12), 1390-1397.
[http://dx.doi.org/10.1038/ni1539 PMID: 17994024] 
[27] 
Parham, C.; Chirica, M.; Timans, J.; Vaisberg, E.; Travis, M.; Cheung, J.; Pflanz, S.; Zhang, R.; Singh, K.P.; Vega, F.; To, W.; Wagner, J.; O’Farrell, A.M.; McClanahan, T.; Zurawski, S.; Hannum, C.; Gorman, D.; Rennick, D.M.; Kastelein, R.A.; de Waal Malefyt, R.; Moore, K.W. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12R beta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol.,  2002, 168(11), 5699-5708.
[http://dx.doi.org/10.4049/jimmunol.168.11.5699 PMID: 12023369] 
[28] 
Gaffen, S.L.; Kramer, J.M.; Yu, J.J.; Shen, F. The IL-17 cytokine family. Vitam. Horm.,  2006, 74, 255-282.
[http://dx.doi.org/10.1016/S0083-6729(06)74010-9 ] [PMID:  17027518] 
[29] 
Martin, D.A.; Towne, J.E.; Kricorian, G.; Klekotka, P.; Gudjonsson, J.E.; Krueger, J.G.; Russell, C.B. The emerging role of IL-17 in the pathogenesis of psoriasis: Preclinical and clinical findings. J. Invest. Dermatol.,  2013, 133(1), 17-26.
[http://dx.doi.org/10.1038/jid.2012.194 PMID: 22673731] 
[30] 
Chiricozzi, A.; Suárez-Fariñas, M.; Fuentes-Duculan, J.; Cueto, I.; Li, K.; Tian, S.; Brodmerkel, C.; Krueger, J.G. Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe Psoriasis vulgaris. Br. J. Dermatol.,  2016, 174(1), 136-145.
[http://dx.doi.org/10.1111/bjd.14034 PMID: 26189551] 
[31] 
Wang, C.Q.F.; Suárez-Fariñas, M.; Nograles, K.E.; Mimoso, C.A.; Shrom, D.; Dow, E.R.; Heffernan, M.P.; Hoffman, R.W.; Krueger, J.G. IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. J. Invest. Dermatol.,  2014, 134(12), 2990-2993.
[http://dx.doi.org/10.1038/jid.2014.268 PMID: 24999591] 
[32] 
Kagami, S.; Rizzo, H.L.; Lee, J.J.; Koguchi, Y.; Blauvelt, A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J. Invest. Dermatol.,  2010, 130(5), 1373-1383.
[http://dx.doi.org/10.1038/jid.2009.399 PMID: 20032993] 
[33] 
Gaffen, S.L. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol.,  2009, 9(8), 556-567.
[http://dx.doi.org/10.1038/nri2586 PMID: 19575028] 
[34] 
Johnston, A.; Fritz, Y.; Dawes, S.M.; Diaconu, D.; Al-Attar, P.M.; Guzman, A.M.; Chen, C.S.; Fu, W.; Gudjonsson, J.E.; McCormick, T.S.; Ward, N.L. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J. Immunol.,  2013, 190(5), 2252-2262.
[http://dx.doi.org/10.4049/jimmunol.1201505 PMID: 23359500] 
[35] 
Muromoto, R.; Hirao, T.; Tawa, K.; Hirashima, K.; Kon, S.; Kitai, Y.; Matsuda, T. IL-17A plays a central role in the expression of psoriasis signature genes through the induction of IκB-ζ in keratinocytes. Int. Immunol.,  2016, 28(9), 443-452.
[http://dx.doi.org/10.1093/intimm/dxw011 PMID: 26944069] 
[36] 
Krueger, J.G.; Fretzin, S.; Suárez-Fariñas, M.; Haslett, P.A.; Phipps, K.M.; Cameron, G.S.; McColm, J.; Katcherian, A.; Cueto, I.; White, T.; Banerjee, S.; Hoffman, R.W. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J. Allergy Clin. Immunol.,  2012, 130(1), 145-54.e9.
[http://dx.doi.org/10.1016/j.jaci.2012.04.024 PMID: 22677045] 
[37] 
Keijsers, R.R.; Joosten, I.; van Erp, P.E.; Koenen, H.J.; van de Kerkhof, P.C. Cellular sources of IL-17 in psoriasis: A paradigm shift? Exp. Dermatol.,  2014, 23(11), 799-803.
[http://dx.doi.org/10.1111/exd.12487 PMID: 25039885] 
[38] 
Lin, A.M.; Rubin, C.J.; Khandpur, R.; Wang, J.Y.; Riblett, M.; Yalavarthi, S.; Villanueva, E.C.; Shah, P.; Kaplan, M.J.; Bruce, A.T. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J. Immunol.,  2011, 187(1), 490-500.
[http://dx.doi.org/10.4049/jimmunol.1100123 PMID: 21606249] 
[39] 
Lande, R.; Botti, E.; Jandus, C.; Dojcinovic, D.; Fanelli, G.; Conrad, C.; Chamilos, G.; Feldmeyer, L.; Marinari, B.; Chon, S.; Vence, L.; Riccieri, V.; Guillaume, P.; Navarini, A.A.; Romero, P.; Costanzo, A.; Piccolella, E.; Gilliet, M.; Frasca, L. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat. Commun.,  2014, 5, 5621.
[http://dx.doi.org/10.1038/ncomms6621 PMID: 25470744] 
[40] 
Krueger, J.G. An autoimmune “attack” on melanocytes triggers psoriasis and cellular hyperplasia. J. Exp. Med.,  2015, 212(13), 2186.
[http://dx.doi.org/10.1084/jem.21213insight3 PMID: 26666753] 
[41] 
Blauvelt, A.; Chiricozzi, A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin. Rev. Allergy Immunol.,  2018, 55(3), 379-390.
[http://dx.doi.org/10.1007/s12016-018-8702-3 PMID: 30109481] 
[42] 
Rønholt, K.; Iversen, L. old and new biological therapies for psoriasis. Int. J. Mol. Sci.,  2017, 18(11)E2297
[http://dx.doi.org/10.3390/ijms18112297 PMID: 29104241] 
[43] 
World Health Organization International Nonproprietary Names (inn) for Biological and Biotechnological Substances.,. http://www.webcitation.org/6rGAZvnd2
[44] 
Strober, B.E.; Armour, K.; Romiti, R.; Smith, C.; Tebbey, P.W.; Menter, A.; Leonardi, C. Biopharmaceuticals and biosimilars in psoriasis: What the dermatologist needs to know. J. Am. Acad. Dermatol.,  2012, 66(2), 317-322.
[http://dx.doi.org/10.1016/j.jaad.2011.08.034 PMID: 22243723] 
[45] 
Dudzinski, D.M.; Kesselheim, A.S. Scientific and legal viability of follow-on protein drugs. N. Engl. J. Med.,  2008, 358(8), 843-849.
[http://dx.doi.org/10.1056/NEJMhle0706973 PMID: 18287608] 
[46] 
Ganzetti, G.; Campanati, A.; Molinelli, E.; Offidani, A. Biologic therapy in inflammatory and immunomediated skin diseases: Safety profile. Curr. Drug Saf.,  2016, 11(1), 12-21.
[http://dx.doi.org/10.2174/1574886310666151014121732 ] [PMID:  26463243] 
[47] 
Campanati, A.; Ganzetti, G.; Di Sario, A.; Damiani, A.; Sandroni, L.; Rosa, L.; Benedetti, A.; Offidani, A. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J. Gastroenterol.,  2013, 48(7), 839-846.
[http://dx.doi.org/10.1007/s00535-012-0678-9 PMID: 23065020] 
[48] 
Bardazzi, F.; Magnano, M.; Campanati, A.; Loconsole, F.; Carpentieri, A.; Potenza, C.; Bernardini, N.; Di Lernia, V.; Carrera, C.; Raone, B.; Patrizi, A.; Loi, C. Biologic therapies in HIV-infected patients with psoriasis: An Italian experience. Acta Derm. Venereol.,  2017, 97(8), 989-990.
[http://dx.doi.org/10.2340/00015555-2698 PMID: 28512671] 
[49] 
Ganzetti, G.; Campanati, A.; Offidani, A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J. Hepatol.,  2015, 7(3), 315-326.
[http://dx.doi.org/10.4254/wjh.v7.i3.315 PMID: 25848461] 
[50] 
Campanati, A.; Ganzetti, G.; Giuliodori, K.; Marra, M.; Bonfigli, A.; Testa, R.; Offidani, A. Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-α inhibitors: Results of a retrospective analysis. Int. J. Dermatol.,  2015, 54(7), 839-845.
[http://dx.doi.org/10.1111/ijd.12706 PMID: 25877149] 
[51] 
European Medicines Agency  Summary of Product Characteristics: Cosentyx 150 mg solution for injection in pre-filled pen or syringe. 2015.http://www.ema.europa.eu
[52] 
European Medicines Agency Summary of Product Characteristics: Taltz 80 mg solution for injection in pre-filled pen or syringe, . 2016.http://www.ema.europa.eu
[53] 
European Medicines Agency Summary of Product Characteristics: Kyntheum 210 mg Solution for Injection in Pre-Filled Syringe,. 2017.http://www.ema.europa.eu
[54] 
European Medicines Agency Summary of Product Characteristics:Tremfya 100 mg solution for injection in pre-filled pen or syringe,. 2017.http://www.ema.europa.eu
[55] 
European Medicines Agency Summary of Product Characteristics:Ilumetri 100 mg solution for injection in pre-filled syringe,. 2018.http://www.ema.europa.eu
[56] 
European Medicines Agency  Summary of Product Characteristics:Skyrizi 75 mg solution for injection in pre-filled syringe,. 2019.http://www.ema.europa.eu
[57] 
Langley, R.G.; Elewski, B.E.; Lebwohl, M.; Reich, K.; Griffiths, C.E.; Papp, K.; Puig, L.; Nakagawa, H.; Spelman, L.; Sigurgeirsson, B.; Rivas, E.; Tsai, T.F.; Wasel, N.; Tyring, S.; Salko, T.; Hampele, I.; Notter, M.; Karpov, A.; Helou, S.; Papavassilis, C. ERASURE Study Group. FIXTURE Study Group. Secukinumab in plaque psoriasis-results of two phase 3 trials. N. Engl. J. Med.,  2014, 371(4), 326-338.
[http://dx.doi.org/10.1056/NEJMoa1314258 PMID: 25007392] 
[58] 
Thaçi, D.; Blauvelt, A.; Reich, K.; Tsai, T.F.; Vanaclocha, F.; Kingo, K.; Ziv, M.; Pinter, A.; Hugot, S.; You, R.; Milutinovic, M. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J. Am. Acad. Dermatol.,  2015, 73(3), 400-409.
[http://dx.doi.org/10.1016/j.jaad.2015.05.013 PMID: 26092291] 
[59] 
Mrowietz, U.; Leonardi, C.L.; Girolomoni, G.; Toth, D.; Morita, A.; Balki, S.A.; Szepietowski, J.C.; Regnault, P.; Thurston, H.; Papavassilis, C. SCULPTURE Study Group. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, non-inferiority trial (SCULPTURE). J. Am. Acad. Dermatol.,  2015, 73(1), 27-36.e1.
[http://dx.doi.org/10.1016/j.jaad.2015.04.011 PMID: 25982539] 
[60] 
Blauvelt, A.; Prinz, J.C.; Gottlieb, A.B.; Kingo, K.; Sofen, H.; Ruer-Mulard, M.; Singh, V.; Pathan, R.; Papavassilis, C.; Cooper, S. FEATURE Study Group. Secukinumab administration by pre-filled syringe: Efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br. J. Dermatol.,  2015, 172(2), 484-493.
[http://dx.doi.org/10.1111/bjd.13348 PMID: 25132411] 
[61] 
Lacour, J.P.; Paul, C.; Jazayeri, S.; Papanastasiou, P.; Xu, C.; Nyirady, J.; Fox, T.; Papavassilis, C. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: Results of the randomized controlled JUNCTURE trial. J. Eur. Acad. Dermatol. Venereol.,  2017, 31(5), 847-856.
[http://dx.doi.org/10.1111/jdv.14073 PMID: 28111801] 
[62] 
Bagel, J.; Duffin, K.C.; Moore, A.; Ferris, L.K.; Siu, K.; Steadman, J.; Kianifard, F.; Nyirady, J.; Lebwohl, M. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J. Am. Acad. Dermatol.,  2017, 77(4), 667-674.
[http://dx.doi.org/10.1016/j.jaad.2017.05.033 PMID: 28780364] 
[63] 
Gottlieb, A.; Sullivan, J.; van Doorn, M.; Kubanov, A.; You, R.; Parneix, A.; Hugot, S.; Milutinovic, M. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J. Am. Acad. Dermatol.,  2017, 76(1), 70-80.
[http://dx.doi.org/10.1016/j.jaad.2016.07.058 PMID: 27707593] 
[64] 
Reich, K.; Sullivan, J.; Arenberger, P. Secukinumab is effective in subjects with moderate to severe plaque psoriasis with significant nail involvement: 16 week results from the TRANSFIGURE study. 23rd World Congress of Dermatology, Vancouver, CanadaJune 8-15, 2015
[65] 
Griffiths, C.E.; Reich, K.; Lebwohl, M.; van de Kerkhof, P.; Paul, C.; Menter, A.; Cameron, G.S.; Erickson, J.; Zhang, L.; Secrest, R.J.; Ball, S.; Braun, D.K.; Osuntokun, O.O.; Heffernan, M.P.; Nickoloff, B.J.; Papp, K. UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet,  2015, 386(9993), 541-551.
[http://dx.doi.org/10.1016/S0140-6736(15)60125-8 ] [PMID:  26072109] 
[66] 
Gordon, K.B.; Blauvelt, A.; Papp, K.A.; Langley, R.G.; Luger, T.; Ohtsuki, M.; Reich, K.; Amato, D.; Ball, S.G.; Braun, D.K.; Cameron, G.S.; Erickson, J.; Konrad, R.J.; Muram, T.M.; Nickoloff, B.J.; Osuntokun, O.O.; Secrest, R.J.; Zhao, F.; Mallbris, L.; Leonardi, C.L. UNCOVER-1 Study Group. UNCOVER-2 Study Group; UNCOVER-3 Study Group. UNCOVER-2 Study Group; UNCOVER-3 Study Group. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N. Engl. J. Med.,  2016, 375(4), 345-356.
[http://dx.doi.org/10.1056/NEJMoa1512711 PMID: 27299809] 
[67] 
Blauvelt, A.; Gooderham, M.; Iversen, L.; Ball, S.; Zhang, L.; Agada, N.O.; Reich, K. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J. Am. Acad. Dermatol.,  2017, 77(5), 855-862.
[http://dx.doi.org/10.1016/j.jaad.2017.06.153 PMID: 28917383] 
[68] 
Papp, K.A.; Leonardi, C. Menter. A.; Ortonne, J.; Krueger, JG.; Kricorian, G.; Aras, G.; Li, J.; Russell, C.B.; Thompson, E.H.; Baumgartner, S. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med.,  2012, 366(13), 1181-1189.
[69] 
Papp, K.A.; Reich, K.; Paul, C.; Blauvelt, A.; Baran, W.; Bolduc, C.; Toth, D.; Langley, R.G.; Cather, J.; Gottlieb, A.B.; Thaçi, D.; Krueger, J.G.; Russell, C.B.; Milmont, C.E.; Li, J.; Klekotka, P.A.; Kricorian, G.; Nirula, A. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br. J. Dermatol.,  2016, 175(2), 273-286.
[http://dx.doi.org/10.1111/bjd.14493 PMID: 26914406] 
[70] 
Xu, G.; Xia, M.; Jiang, C.; Yu, Y.; Wang, G.; Yuan, J.; Duan, X. Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis. J. Pharmacol. Sci.,  2019, 139(4), 289-303.
[http://dx.doi.org/10.1016/j.jphs.2018.12.006 PMID: 30922656] 
[71] 
Lebwohl, M.; Strober, B.; Menter, A.; Gordon, K.; Weglowska, J.; Puig, L.; Papp, K.; Spelman, L.; Toth, D.; Kerdel, F.; Armstrong, A.W.; Stingl, G.; Kimball, A.B.; Bachelez, H.; Wu, J.J.; Crowley, J.; Langley, R.G.; Blicharski, T.; Paul, C.; Lacour, J.P.; Tyring, S.; Kircik, L.; Chimenti, S.; Callis Duffin, K.; Bagel, J.; Koo, J.; Aras, G.; Li, J.; Song, W.; Milmont, C.E.; Shi, Y.; Erondu, N.; Klekotka, P.; Kotzin, B.; Nirula, A. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N. Engl. J. Med.,  2015, 373(14), 1318-1328.
[http://dx.doi.org/10.1056/NEJMoa1503824 ] [PMID:  26422722] 
[72] 
Blauvelt, A.; Lebwohl, M.G.; Green, L.J. Median time to treatment response in patients with mderate-to-severe plaque psoriasis treated with brodalumab 210mg or ustekinumab: A pooled analysis of data from two phase 3 randomized clinical trials (amagine-2 and amagine-3). J. Clin. Aesthet. Dermatol.,  2017, 10(5)(Suppl. 1), S22-S23.
[73] 
Lønnberg, A.S.; Zachariae, C.; Skov, L. Targeting of interleukin-17 in the treatment of psoriasis. Clin. Cosmet. Investig. Dermatol.,  2014, 7, 251-259.
[http://dx.doi.org/10.2147/CCID.S67534 PMID: 25246805] 
[74] 
Iwakura, Y.; Ishigame, H.; Saijo, S.; Nakae, S. Functional specialization of interleukin-17 family members. Immunity,  2011, 34(2), 149-162.
[http://dx.doi.org/10.1016/j.immuni.2011.02.012 PMID: 21349428] 
[75] 
Blauvelt, A.; Papp, K.A.; Griffiths, C.E.; Randazzo, B.; Wasfi, Y.; Shen, Y.K.; Li, S.; Kimball, A.B. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J. Am. Acad. Dermatol.,  2017, 76(3), 405-417.
[http://dx.doi.org/10.1016/j.jaad.2016.11.041 PMID: 28057360] 
[76] 
Reich, K.; Armstrong, A.W.; Foley, P.; Song, M.; Wasfi, Y.; Randazzo, B.; Li, S.; Shen, Y.K.; Gordon, K.B. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J. Am. Acad. Dermatol.,  2017, 76(3), 418-431.
[http://dx.doi.org/10.1016/j.jaad.2016.11.042 PMID: 28057361] 
[77] 
Langley, R.G.; Tsai, T.F.; Flavin, S.; Song, M.; Randazzo, B.; Wasfi, Y.; Jiang, J.; Li, S.; Puig, L. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, phase III NAVIGATE trial. Br. J. Dermatol.,  2018, 178(1), 114-123.
[http://dx.doi.org/10.1111/bjd.15750 PMID: 28635018] 
[78] 
Gordon, K.B.; Strober, B.; Lebwohl, M.; Augustin, M.; Blauvelt, A.; Poulin, Y.; Papp, K.A.; Sofen, H.; Puig, L.; Foley, P.; Ohtsuki, M.; Flack, M.; Geng, Z.; Gu, Y.; Valdes, J.M.; Thompson, E.H.Z.; Bachelez, H. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet,  2018, 392(10148), 650-661.
[http://dx.doi.org/10.1016/S0140-6736(18)31713-6 ] [PMID:  30097359] 
[79] 
Gordon, K.B.; Strober, B. Lebwohl. M.; Augustin, M.; Blauvelt, A.; Poulin, Y.; Papp, K.A.; Sofen, H.; Puig, L.; Foley, P.; Ohtsuki, M.; Flack, M.; Geng, Z.; Gu, Y.; Valdes, J.M.; Thompson, E.H.Z.; Bachelez, H. Efficacy and Safety of Risankizumab: Results from two double-blind, Placebo- and ustekinumab-controlled, phase 3 trials in moderate-to-severe plaque psoriasis. Lancet,  2018, 392(10148), 650-661.
[http://dx.doi.org/10.1016/S0140-6736(18)31713-6 ] [PMID:  30097359] 
[80] 
Reich, K.; Gooderham, M.; Thaçi, D.; Crowley, J.J.; Ryan, C.; Krueger, J.G.; Tsai, T.F.; Flack, M.; Gu, Y.; Williams, D.A.; Thompson, E.H.Z.; Paul, C. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): A randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet, 2019.
[81] 
Reich, K.; Papp, K.A.; Blauvelt, A.; Tyring, S.K.; Sinclair, R.; Thaçi, D.; Nograles, K.; Mehta, A.; Cichanowitz, N.; Li, Q.; Liu, K.; La Rosa, C.; Green, S.; Kimball, A.B. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): Results from two randomised controlled, phase 3 trials. Lancet,  2017, 390(10091), 276-288.
[http://dx.doi.org/10.1016/S0140-6736(17)31279-5 ] [PMID:  28596043] 
[82] 
Papp, K.A.; Reich, K.; Blauvelt, A.; Kimball, A.B.; Gooderham, M.; Tyring, S.K.; Sinclair, R.; Thaci, D.; Li, Q.; Cichanowitz, N.; Green, S.; La Rosa, C. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: Pooled analysis of three randomized controlled trials at weeks 12 and 28. J. Eur. Acad. Dermatol. Venereol.,  2019, 33(6), 1098-1106.
[http://dx.doi.org/10.1111/jdv.15400 PMID: 30838709] 
[83] 
Papp, K.A.; Lebwohl, M.G. Onset of action of biologics in patients with moderate-to-severe psoriasis. J. Drugs Dermatol.,  2017, 17(3), 247-250.
[PMID:  29537442] 
[84] 
Egeberg, A.; Ottosen, M.B.; Gniadecki, R.; Broesby-Olsen, S.; Dam, T.N.; Bryld, L.E.; Rasmussen, M.K.; Skov, L. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br. J. Dermatol.,  2018, 178(2), 509-519.
[http://dx.doi.org/10.1111/bjd.16102 PMID: 29094341] 
[85] 
Amin, M.; Darji, K.; No, D.J.; Wu, J.J. Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis. J. Eur. Acad. Dermatol. Venereol.,  2017, 31(10), 1627-1632.
[http://dx.doi.org/10.1111/jdv.14451 PMID: 28667777] 
[86] 
Bissonnette, R.; Luger, T.; Thaçi, D.; Toth, D.; Lacombe, A.; Xia, S.; Mazur, R.; Patekar, M.; Charef, P.; Milutinovic, M.; Leonardi, C.; Mrowietz, U. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J. Eur. Acad. Dermatol. Venereol.,  2018, 32(9), 1507-1514.
[http://dx.doi.org/10.1111/jdv.14878 PMID: 29444376] 
[87] 
Gottlieb, A.B.; Kubanov, A.; van Doorn, M.; Sullivan, J.; Papp, K.A.; You, R.; Regnault, P.; Frueh, J.A. Sustained efficacy of secukinumab in subjects with moderate-to-severe palmoplantar psoriasis: 2.5-Year results from gesture, a randomized, double-blind, placebo-controlled trial. Br. J. Dermatol.,  2020, 182(4), 889-899.
[88] 
Reich, K.; Puig, L.; Szepietowski, J.C.; Paul, C.; Lacour, J.P.; Tsianakas, A.; Sieder, C.; Rissler, M.; Pournara, E.; Orsenigo, R. Secukinumab dosing optimization in patients with moderate to severe plaque psoriasis: Results from the randomised, open-label OPTIMISE study. Br. J. Dermatol., 2019.
[89] 
Farahnik, B.; Beroukhim, K.; Zhu, T.H.; Abrouk, M.; Nakamura, M.; Singh, R.; Lee, K.; Bhutani, T.; Koo, J. Ixekizumab for the treatment of psoriasis: A review of phase III trials. Dermatol. Ther. (Heidelb.),  2016, 6(1), 25-37.
[http://dx.doi.org/10.1007/s13555-016-0102-0 PMID: 26910853] 
[90] 
Yosipovitch, G.; Reich, A.; Steinhoff, M.; Beselin, A.; Kent, T.; Dossenbach, M.; Berggren, L.; Henneges, C.; Luger, T. Impact of ixekizumab treatment on itch and psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis: An integrated analysis of two phase III randomized studies. Dermatol. Ther. (Heidelb.),  2018, 8(4), 621-637.
[http://dx.doi.org/10.1007/s13555-018-0267-9 PMID: 30465321] 
[91] 
Reich, K.; Augustin, M. Thaçi, D.; Pinter, A.; Leutz, A.; Henneges, C.; Schneider, E.; Schacht, A.; Dossenbach, M.; Mrowietz, U. A 24-week multicentre, randomised, open-label, parallel-group study comparing the efficacy and safety of ixekizumab to fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment. Br. J. Dermatol.,  2020, 182(4), 869-879.
[http://dx.doi.org/10.1111/bjd.18384 PMID: 31376153] 
[92] 
Kerdel, F.; Zaiac, M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol. Ther. (Heidelb.),  2015, 28(6), 390-403.
[http://dx.doi.org/10.1111/dth.12267 PMID: 26258910] 
[93] 
Van Lümig, P.P.; Lecluse, L.L.; Driessen, R.J.; Spuls, P.I.; Boezeman, J.B.; van de Kerkhof, P.C.; De Jong, E.M. Switching from etanercept to adalimumab is effective and safe: Results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br. J. Dermatol.,  2010, 163(4), 838-846.
[http://dx.doi.org/10.1111/j.1365-2133.2010.09950.x PMID: 20649798] 
[94] 
Gisondi, P.; Amerio, P.; Amoroso, G.F.; Antonucci, V.A.; Bardazzi, F.; Buongiorno, M.R.; Bruni, P.; Campanati, A.; Caproni, M.; Carlesimo, M.; Carrera, C.G.; Cianchino, G.; Cimmino, G.; Costanzo, A.; Cozzani, E.; Dapavo, P.; D’amico, D.; De Simone, C.; Del Giglio, M.; Di Nuzzo, S.; Gai, F.; Galluccio, A.G.; Goffredo, A.; Gualdi, G.; Guarneri, C.; Kokelj, F.; Lasagni, C.; Loconsole, F.; Longo, V.; Malagoli, P.; Miracapillo, A.; Mugheddu, C.; Parodi, A.; Pellegrino, M.; Peserico, A.; Piaserico, S.; Pistone, G.; Potenza, C.; Plumari, A.; Stingeni, L.; Strippoli, D.; Travaglino, M.; Girolomoni, G. Optimization of systemic treatments for chronic plaque psoriasis. Recommendations for switching and transitioning. G. Ital. Dermatol. Venereol.,  2013, 148(6)(Suppl. 1), 1-10.
[PMID:  24675369] 
[95] 
Piaserico, S.; Cazzaniga, S.; Chimenti, S.; Giannetti, A.; Maccarone, M.; Picardo, M.; Peserico, A.; Naldi, L. Psocare Study Group. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare registry. J. Am. Acad. Dermatol.,  2014, 70(2), 257-62.e3.
[http://dx.doi.org/10.1016/j.jaad.2013.10.019 PMID: 24355410] 
[96] 
Bissonnette, R.; Bolduc, C.; Poulin, Y.; Guenther, L.; Lynde, C.W.; Maari, C. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. J. Am. Acad. Dermatol.,  2010, 63(2), 228-234.
[http://dx.doi.org/10.1016/j.jaad.2009.08.040 PMID: 20494479] 
[97] 
Bokor-Billmann, T.; Schäkel, K. No need to change the drug class: Ixekizumab- following secukinumab-therapy in psoriasis. J. Dermatolog. Treat.,  2018, 11, 1-5.
[PMID:  30051725] 
[98] 
Georgakopoulos, J.R.; Phung, M.; Ighani, A.; Yeung, J. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies. J. Am. Acad. Dermatol.,  2018, 79(1), 155-157.
[http://dx.doi.org/10.1016/j.jaad.2018.01.003 PMID: 29307635] 
[99] 
Conti, A. Peccerillo. F.; Amerio, P.; Balato, A.; Bardazzi, F.; Bianchi, L.; Burlando, M.; Cannavò, S.P.; Chiricozzi, A.; Dapavo, P.; De Simone, C.; Fargnoli, M.C.; Gambardella, A.; Gisondi, P.; Malagoli, P.; Malara, G.; Mugheddu, C.; Offidani, A.M.; Piaserico, S.; Prignano, F.; Stingeni, L.; Pellacani G. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: Results from a multicentre experience. Br. J. Dermatol.,  2019, 180(6), 1547-1548.
[100] 
Lo, Y.; Tsai, T.F. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: A case series. Br. J. Dermatol.,  2019, 181(5), 1106-1107.
[http://dx.doi.org/10.1111/bjd.18174 PMID: 31145806] 
[101] 
Warren, R.B.; Brnabic, A.; Saure, D.; Langley, R.G.; See, K.; Wu, J.J.; Schacht, A.; Mallbris, L.; Nast, A. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. Br. J. Dermatol.,  2018, 178(5), 1064-1071.
[http://dx.doi.org/10.1111/bjd.16140 PMID: 29171861] 
[102] 
Sherman, S.; Solomon Cohen, E.; Amitay-Laish, I.; Hodak, E.; Pavlovsky, L. IL-17A inhibitor switching - efficacy of ixekizumab following secukinumab failure. A single-center experience. Acta Derm. Venereol.,  2019, 99(9), 769-773.
[http://dx.doi.org/10.2340/00015555-3200 PMID: 31017250] 
[103] 
Umezawa, Y.; Torisu-Itakura, H.; Morisaki, Y.; ElMaraghy, H.; Nakajo, K.; Akashi, N.; Saeki, H. Japanese ixekizumab study group. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: Impact of treatment withdrawal and retreatment of ixekizumab. J. Eur. Acad. Dermatol. Venereol.,  2019, 33(3), 568-576.
[http://dx.doi.org/10.1111/jdv.15292 PMID: 30325534] 
[104] 
Galluzzo, M.; D’Adamio, S.; Massaro, A.; Piccolo, A.; Bianchi, L.; Talamonti, M. Spotlight on brodalumab in the treatment of plaque psoriasis: The evidence to date. Clin. Cosmet. Investig. Dermatol.,  2019, 12, 311-321.
[http://dx.doi.org/10.2147/CCID.S165605 PMID: 31118733] 
[105] 
Papp, K.; Leonardi, C.; Menter, A.; Thompson, E.H.; Milmont, C.E.; Kricorian, G.; Nirula, A.; Klekotka, P. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J. Am. Acad. Dermatol.,  2014, 71(6), 1183-1190.e3.
[http://dx.doi.org/10.1016/j.jaad.2014.08.039 PMID: 25313095] 
[106] 
Sawyer, L.M.; Cornic, L.; Levin, L.Å.; Gibbons, C.; Møller, A.H.; Jemec, G.B. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. J. Eur. Acad. Dermatol. Venereol.,  2019, 33(2), 355-366.
[http://dx.doi.org/10.1111/jdv.15277 PMID: 30289198] 
[107] 
Nakamura, M.; Lee, K.; Jeon, C.; Sekhon, S.; Afifi, L.; Yan, D.; Lee, K.; Bhutani, T. Guselkumab for the treatment of psoriasis: A review of phase III trials. Dermatol. Ther. (Heidelb.),  2017, 7(3), 281-292.
[http://dx.doi.org/10.1007/s13555-017-0187-0 PMID: 28639011] 
[108] 
Ohtsuki, M.; Kubo, H.; Morishima, H.; Goto, R.; Zheng, R.; Nakagawa, H. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J. Dermatol.,  2018, 45(9), 1053-1062.
[http://dx.doi.org/10.1111/1346-8138.14504 PMID: 29905383] 
[109] 
Griffiths, C.E.M.; Papp, K.A.; Kimball, A.B.; Randazzo, B.; Song, M.; Li, S.; Shen, Y.K.; Blauvelt, A. Long-term efficacy of guselkumab for the treatment of moderate-to-severe psoriasis: Results from the phase 3 VOYAGE 1 trial through two years. J. Drugs Dermatol.,  2018, 17(8), 826-832.
[PMID:  30124721] 
[110] 
Yang, E.J.; Smith, M.P.; Ly, K.; Bhutani, T. Evaluating guselkumab: An anti-IL-23 antibody for the treatment of plaque psoriasis. Drug Des. Devel. Ther.,  2019, 13, 1993-2000.
[http://dx.doi.org/10.2147/DDDT.S137588 PMID: 31354244] 
[111] 
Reich, K.; Armstrong, A.W.; Langley, R.G.; Flavin, S.; Randazzo, B.; Li, S.; Hsu, M.C.; Branigan, P.; Blauvelt, A. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): Results from a phase 3, randomised controlled trial. Lancet,  2019, 394(10201), 831-839.
[112] 
Blauvelt, A.; Sofen, H.; Papp, K.; Gooderham, M.; Tyring, S.; Zhao, Y.; Lowry, S.; Mendelsohn, A.; Parno, J.; Reich, K. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: A pooled analysis of two randomized controlled trials. J. Eur. Acad. Dermatol. Venereol.,  2019, 33(12), 2305-2312.
[http://dx.doi.org/10.1111/jdv.15862 PMID: 31407394] 
[113] 
Elewski, B.; Menter, A.; Crowley, J.; Tyring, S.; Zhao, Y.; Lowry, S.; Rozzo, S.; Mendelsohn, A.M.; Parno, J.; Gordon, K. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. J. Dermatolog. Treat.,  2020, 31(8), 763-768.
[http://dx.doi.org/10.1080/09546634.2019.1640348 ] [PMID:  31268369] 
[114] 
Reich, K.; Warren, R.B.; Iversen, L.; Puig, L.; Pau-Charles, I.; Igarashi, A.; Ohtsuki, M.; Falqués, M.; Harmut, M.; Rozzo, S.; Lebwohl, M.G.; Cantrell, W.; Blauvelt, A.; Thaçi, D. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br. J. Dermatol.,  2020, 182(3), 605-617.
[PMID:  31218661] 
[115] 
Machado, Á.; Torres, T. Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: Evidence to date. Psoriasis (Auckl),  2018, 8, 83-92.
[http://dx.doi.org/10.2147/PTT.S165943 PMID: 30519540] 
[116] 
Sawyer, L.M.; Malottki, K.; Sabry-Grant, C.; Yasmeen, N.; Wright, E.; Sohrt, A.; Borg, E.; Warren, R.B. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLoS One,  2019, 14(8)e0220868
[http://dx.doi.org/10.1371/journal.pone.0220868 PMID: 31412060] 
[117] 
Rompoti, N.; Katsimbri, P.; Kokkalis, G.; Boumpas, D.; Ikonomidis, I.; Theodoropoulos, K.; Rigopoulos, D.; Papadavid, E. Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study. Dermatol. Ther. (Heidelb.),  2019, 32(5)e13006
[http://dx.doi.org/10.1111/dth.13006 PMID: 31228319] 
[118] 
Megna, M.; Di Costanzo, L.; Argenziano, G.; Balato, A.; Colasanti, P.; Cusano, F.; Galluccio, A.G.; Gambardella, A.; Lembo, S.; Mozzillo, R.; Scotto Di Luzio, G.; Fabbrocini, G.; Balato, N. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin. Biol. Ther.,  2019, 19(8), 855-861.
[http://dx.doi.org/10.1080/14712598.2019.1622678 ] [PMID:  31140882] 
[119] 
Galluzzo, M.; Talamonti, M.; De Simone, C.; D’Adamio, S.; Moretta, G.; Tambone, S.; Caldarola, G.; Fargnoli, M.C.; Peris, K.; Bianchi, L. Secukinumab in moderate-to-severe plaque psoriasis: A multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin. Biol. Ther.,  2018, 18(7), 727-735.
[http://dx.doi.org/10.1080/14712598.2018.1481503 ] [PMID:  29798698] 
[120] 
Ortiz-Salvador, J.M.; Saneleuterio-Temporal, M.; Magdaleno-Tapial, J.; Velasco-Pastor, M.; Pujol-Marco, C.; Sahuquillo-Torralba, A.; Mateu-Puchades, A.; Pitarch-Bort, G.; Marí-Ruiz, J.I.; Mataix-Díaz, J.; Montesinos-Villaescusa, E.; Miralles-Botella, J.; García-Fernández, L.; Martorell-Calatayud, A.; Belinchón-Romero, I.; Sánchez-Carazo, J.L.; Pérez-Ferriols, A. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients. J. Am. Acad. Dermatol.,  2019, 81(2), 427-432.
[http://dx.doi.org/10.1016/j.jaad.2019.02.062 PMID: 30872150] 
[121] 
Notario, J.; Deza, G.; Vilarrasa, E.; Valentí, F.; Muñoz, C.; Mollet, J.; Rocamora, V.; Carrascosa, J.M.; Del Alcázar, E.; Alsina, M.; Vidal, D.; Puig, L.; López-Ferrer, A.; Riera, J.; Gallardo, F.; Ferran, M. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: A 52-week, multicenter, retrospective study in Spain. J. Dermatolog. Treat.,  2019, 30(5), 424-429.
[http://dx.doi.org/10.1080/09546634.2018.1528000 ] [PMID:  30244618] 
[122] 
Ferrières, L.; Konstantinou, M.P.; Bulai Livideanu, C.; Hegazy, S.; Tauber, M.; Amelot, F.; Paul, C. Long-term continuation with secukinumab in psoriasis: Association with patient profile and initial psoriasis clearance. Clin. Exp. Dermatol.,  2019, 44(7), e230-e234.
[http://dx.doi.org/10.1111/ced.13999 PMID: 31055846] 
[123] 
Strober, B.E.; Germino, R.; Guana, A.; Greenberg, J.D.; Litman, H.J.; Guo, N.; Lebwohl, M. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. J. Dermatolog. Treat.,  2020, 31(4), 333-341.
[http://dx.doi.org/10.1080/09546634.2019.1603361 ] [PMID:  31035822] 
[124] 
Diotallevi, F.; Campanati, A.; Radi, G.; Molinelli, E.; Offidani, A. Ixekizumab for treatment of moderate to severe plaque psoriasis: real world clinical experience. G. Ital. Dermatol. Venereol., 2019. Epub ahead of print
[http://dx.doi.org/10.23736/S0392-0488.18.06094-7 ] [PMID:  30428651] 
[125] 
Damiani, G.; Conic, R.R.Z.; Pigatto, P.D.M.; Bragazzi, N.L.; Pacifico, A.; Malagoli, P. Young Dermatologists Italian Network. From randomized clinical trials to real life data. An Italian clinical experience with ixekizumab and its management. Dermatol. Ther. (Heidelb.),  2019, 32(3)e12886
[http://dx.doi.org/10.1111/dth.12886 PMID: 30942952] 
[126] 
Deza, G.; Notario, J.; Lopez-Ferrer, A.; Vilarrasa, E.; Ferran, M.; Del Alcazar, E.; Carrascosa, J.M.; Corral, M.; Salleras, M.; Ribera, M.; Puig, L.; Pujol, R.M.; Vidal, D.; Gallardo, F. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: A multicentre retrospective study. J. Eur. Acad. Dermatol. Venereol.,  2019, 33(3), 553-559.
[http://dx.doi.org/10.1111/jdv.15288 PMID: 30317679] 
[127] 
Magdaleno-Tapial, J.; Carmena-Ramón, R.; Valenzuela-Oñate, C.; Ortiz-Salvador, J.M.; Sabater-Abad, J.; Hernández-Bel, P.; Gimeno-Carpio, E.; Sánchez-Carazo, J.L.; Pérez-Ferriols, A. Efficacy and safety of ixekizumab in a real-life practice: A retrospective bicentric study. Actas Dermosifiliogr.,  2019, 110(7), 585-589.
[http://dx.doi.org/10.1016/j.adengl.2019.06.004 PMID: 31006480] 
[128] 
Pinter, A.; Bonnekoh, B.; Hadshiew, I.M.; Zimmer, S. Brodalumab for the treatment of moderate-to-severe psoriasis: Case series and literature review. Clin. Cosmet. Investig. Dermatol.,  2019, 12(12), 509-517.
[http://dx.doi.org/10.2147/CCID.S211938 PMID: 31372022] 
[129] 
Zhang, L.; Yang, H.; Chen, Q.; Zhao, J. Adverse drug events observed with 150 mg versus 300 mg secukinumab for the treatment of moderate to severe plaque psoriasis: A systematic review and meta-analysis. Medicine (Baltimore),  2019, 98(2)e14042
[http://dx.doi.org/10.1097/MD.0000000000014042 ] [PMID:  30633199] 
[130] 
van de Kerkhof, P.C.; Griffiths, C.E.; Reich, K.; Leonardi, C.L.; Blauvelt, A.; Tsai, T.F.; Gong, Y.; Huang, J.; Papavassilis, C.; Fox, T. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J. Am. Acad. Dermatol.,  2016, 75(1), 83-98.e4.
[http://dx.doi.org/10.1016/j.jaad.2016.03.024 PMID: 27180926] 
[131] 
Armstrong, A.W.; Papp, K.; Kircik, L. Secukinumab: Review of clinical evidence from the Pivotal Studies ERASURE, FIXTURE, and CLEAR. J. Clin. Aesthet. Dermatol.,  2016, 9(6)(Suppl. 1), S7-S12.
[PMID:  28439341] 
[132] 
Blauvelt, A. Safety of secukinumab in the treatment of psoriasis. Expert Opin. Drug Saf.,  2016, 15(10), 1413-1420.
[http://dx.doi.org/10.1080/14740338.2016.1221923 ] [PMID:  27545070] 
[133] 
Deodhar, A.; Mease, P.J.; McInnes, I.B.; Baraliakos, X.; Reich, K.; Blauvelt, A.; Leonardi, C.; Porter, B.; Das Gupta, A.; Widmer, A.; Pricop, L.; Fox, T. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: Integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res. Ther.,  2019, 21(1), 111.
[http://dx.doi.org/10.1186/s13075-019-1882-2] 
[134] 
Mease, P.J.; Kavanaugh, A.; Reimold, A.; Tahir, H.; Rech, J.; Hall, S.; Geusens, P.; Pellet, P.; Delicha, E.M.; Mpofu, S.; Pricop, L. Secukinumab in the treatment of psoriatic arthritis: Efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open,  2018, 4(2)e000723
[http://dx.doi.org/10.1136/rmdopen-2018-000723] 
[135] 
Shelton, S.K.; Bai, S.R.; Jordan, J.K.; Sheehan, A.H. Ixekizumab: A review of its use for the management of moderate to severe plaque psoriasis. Ann. Pharmacother.,  2019, 53(3), 276-284.
[http://dx.doi.org/10.1177/1060028018799982 PMID: 30187769] 
[136] 
Kazemi, T.; Farahnik, B.; Koo, J.; Beroukhim, K. Emerging targeted therapies for plaque psoriasis - impact of ixekizumab. Clin. Cosmet. Investig. Dermatol.,  2017, 10(10), 133-139.
[http://dx.doi.org/10.2147/CCID.S111007 PMID: 28461763] 
[137] 
Langley, R.G.; Kimball, A.B.; Nak, H.; Xu, W.; Pangallo, B.; Osuntokun, O.O.; Agada, N.; Reich, K. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. J. Eur. Acad. Dermatol. Venereol.,  2019, 33(2), 333-339.
[http://dx.doi.org/10.1111/jdv.15242 PMID: 30198588] 
[138] 
Mease, P.; Roussou, E.; Burmester, G.R.; Goupille, P.; Gottlieb, A.; Moriarty, S.R.; Benichou, O.; Adams, D.H.; Xu, W.; Nash, P. Safety of ixekizumab in patients with psoriatic arthritis: Results from a pooled analysis of three clinical trials. Arthritis Care Res. (Hoboken),  2019, 71(3), 367-378.
[http://dx.doi.org/10.1002/acr.23738 PMID: 30156760] 
[139] 
Farahnik, B.; Beroukhim, K.; Abrouk, M.; Nakamura, M.; Zhu, T.H.; Singh, R.; Lee, K.; Bhutani, T.; Koo, J. Brodalumab for the Treatment of psoriasis: A review of phase III trials. Dermatol. Ther. (Heidelb.),  2016, 6(2), 111-124.
[http://dx.doi.org/10.1007/s13555-016-0121-x PMID: 27221323] 
[140] 
Chiricozzi, A.; Romanelli, M.; Saraceno, R.; Torres, T. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. Expert Opin. Drug Saf.,  2016, 15(12), 1653-1659.
[http://dx.doi.org/10.1080/14740338.2016.1228872 ] [PMID:  27554637] 
[141] 
Lebwohl, M.G.; Papp, K.A.; Marangell, L.B.; Koo, J.; Blauvelt, A.; Gooderham, M.; Wu, J.J.; Rastogi, S.; Harris, S.; Pillai, R.; Israel, R.J. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. J. Am. Acad. Dermatol.,  2018, 78(1), 81-89.e5.
[http://dx.doi.org/10.1016/j.jaad.2017.08.024 PMID: 28985956] 
[142] 
Wechter, T.; Cline, A.; Feldman, S.R. Targeting p19 as a treatment option for psoriasis: An evidence-based review of guselkumab. Ther. Clin. Risk Manag.,  2018, 14(14), 1489-1497.
[http://dx.doi.org/10.2147/TCRM.S177127 PMID: 30174431] 
[143] 
Blauvelt, A.; Reich, K.; Papp, K.A.; Kimball, A.B.; Gooderham, M.; Tyring, S.K.; Sinclair, R.; Thaçi, D.; Li, Q.; Cichanowitz, N.; Green, S.; La Rosa, C. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: Pooled analysis of three randomized controlled trials. Br. J. Dermatol.,  2018, 179(3), 615-622.
[http://dx.doi.org/10.1111/bjd.16724 PMID: 29742274] 
[144] 
Krueger, J.G.; Ferris, L.K.; Menter, A.; Wagner, F.; White, A.; Visvanathan, S.; Lalovic, B.; Aslanyan, S.; Wang, E.E.; Hall, D.; Solinger, A.; Padula, S.; Scholl, P. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol.,  2015, 136(1), 116-124.e7.
[http://dx.doi.org/10.1016/j.jaci.2015.01.018 PMID: 25769911] 
[145] 
Papp, K.A.; Blauvelt, A.; Bukhalo, M.; Gooderham, M.; Krueger, J.G.; Lacour, J.P.; Menter, A.; Philipp, S.; Sofen, H.; Tyring, S.; Berner, B.R.; Visvanathan, S.; Pamulapati, C.; Bennett, N.; Flack, M.; Scholl, P.; Padula, S.J. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N. Engl. J. Med.,  2017, 376(16), 1551-1560.
[http://dx.doi.org/10.1056/NEJMoa1607017 PMID: 28423301] 
[146] 
Papp, K.; Gottlieb, A.B.; Naldi, L.; Pariser, D.; Ho, V.; Goyal, K.; Fakharzadeh, S.; Chevrier, M.; Calabro, S.; Langholff, W.; Krueger, G. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J. Drugs Dermatol.,  2015, 14(7), 706-714.
[PMID:  26151787] 
[147] 
Papp, K.A.; Griffiths, C.E.; Gordon, K.; Lebwohl, M.; Szapary, P.O.; Wasfi, Y.; Chan, D.; Hsu, M.C.; Ho, V.; Ghislain, P.D.; Strober, B.; Reich, K. PHOENIX 1 Investigators; PHOENIX 2 Investigators; ACCEPT Investigators. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: Final results from 5 years of follow-up. Br. J. Dermatol.,  2013, 168(4), 844-854.
[http://dx.doi.org/10.1111/bjd.12214 PMID: 23301632] 
[148] 
Crowley, J.J.; Warren, R.B.; Cather, J.C. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J. Eur. Acad. Dermatol. Venereol.,  2019, 33(9), 1676-1684.
[http://dx.doi.org/10.1111/jdv.15653 PMID: 31054215] 
[149] 
Xu, S.; Zhang, X.; Pan, M.; Shuai, Z.; Xu, S.; Pan, F. Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis. Int. Immunopharmacol.,  2019, 26105841
[150] 
Erichsen, C.Y.; Jensen, P.; Kofoed, K. Biologic therapies targeting the interleukin (IL)-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis. J. Eur. Acad. Dermatol. Venereol.,  2020, 34(1), 30-38.
[http://dx.doi.org/10.1111/jdv.15879 PMID: 31419343] 
[151] 
Hueber, W.; Sands, B.E.; Lewitzky, S.; Vandemeulebroecke, M.; Reinisch, W.; Higgins, P.D.; Wehkamp, J.; Feagan, B.G.; Yao, M.D.; Karczewski, M.; Karczewski, J.; Pezous, N.; Bek, S.; Bruin, G.; Mellgard, B.; Berger, C.; Londei, M.; Bertolino, A.P.; Tougas, G.; Travis, S.P. Secukinumab in Crohn’s disease study group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut,  2012, 61(12), 1693-1700.
[http://dx.doi.org/10.1136/gutjnl-2011-301668 PMID: 22595313] 
[152] 
Targan, S.R.; Feagan, B.; Vermeire, S.; Panaccione, R.; Melmed, G.Y.; Landers, C.; Li, D.; Russell, C.; Newmark, R.; Zhang, N.; Chon, Y.; Hsu, Y.H.; Lin, S.L.; Klekotka, P. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn’s disease. Am. J. Gastroenterol.,  2016, 111(11), 1599-1607.
[http://dx.doi.org/10.1038/ajg.2016.298 PMID: 27481309] 
[153] 
Schreiber, S.; Colombel, J.F.; Feagan, B.G.; Reich, K.; Deodhar, A.A.; McInnes, I.B.; Porter, B.; Das Gupta, A.; Pricop, L.; Fox, T. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: A retrospective analysis of pooled data from 21 clinical trials. Ann. Rheum. Dis.,  2019, 78(4), 473-479.
[http://dx.doi.org/10.1136/annrheumdis-2018-214273 ] [PMID:  30674475] 
[154] 
Fries, W.; Belvedere, A.; Cappello, M.; Orlando, A.; Trifirò, G. Inflammatory bowel disease onset during secukinumab treatment: Real concern or just an expression of dysregulated immune response? Clin. Drug Investig.,  2019, 39(8), 799-803.
[http://dx.doi.org/10.1007/s40261-019-00803-7 PMID: 31168691] 
[155] 
Reich, K.; Leonardi, C.; Langley, R.G.; Warren, R.B.; Bachelez, H.; Romiti, R.; Ohtsuki, M.; Xu, W.; Acharya, N.; Solotkin, K.; Colombel, J.F.; Hardin, D.S. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J. Am. Acad. Dermatol.,  2017, 76(3), 441-448.e2.
[http://dx.doi.org/10.1016/j.jaad.2016.10.027 PMID: 28027825] 
[156] 
Yamada, A.; Wang, J.; Komaki, Y.; Komaki, F.; Micic, D.; Sakuraba, A. Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents. Aliment. Pharmacol. Ther.,  2019, 50(4), 373-385.
[http://dx.doi.org/10.1111/apt.15397 PMID: 31309607] 
[157] 
Hohenberger, M.; Cardwell, L.A.; Oussedik, E.; Feldman, S.R. Interleukin-17 inhibition: Role in psoriasis and inflammatory bowel disease. J. Dermatolog. Treat.,  2018, 29(1), 13-18.
[http://dx.doi.org/10.1080/09546634.2017.1329511 ] [PMID:  28521565] 
[158] 
Feagan, B.G.; Sandborn, W.J.; D’Haens, G.; Panés, J.; Kaser, A.; Ferrante, M.; Louis, E.; Franchimont, D.; Dewit, O.; Seidler, U.; Kim, K.J.; Neurath, M.F.; Schreiber, S.; Scholl, P.; Pamulapati, C.; Lalovic, B.; Visvanathan, S.; Padula, S.J.; Herichova, I.; Soaita, A.; Hall, D.B.; Böcher, W.O. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: A randomised, double-blind, placebo-controlled phase 2 study. Lancet,  2017, 389(10080), 1699-1709.
[http://dx.doi.org/10.1016/S0140-6736(17)30570-6 ] [PMID:  28411872] 
[159] 
Feagan, B.G.; Panés, J.; Ferrante, M.; Kaser, A.; D’Haens, G.R.; Sandborn, W.J.; Louis, E.; Neurath, M.F.; Franchimont, D.; Dewit, O.; Seidler, U.; Kim, K.J.; Selinger, C.; Padula, S.J.; Herichova, I.; Robinson, A.M.; Wallace, K.; Zhao, J.; Minocha, M.; Othman, A.A.; Soaita, A.; Visvanathan, S.; Hall, D.B.; Böcher, W.O. Risankizumab in patients with moderate to severe Crohn’s disease: an open-label extension study. Lancet Gastroenterol. Hepatol.,  2018, 3(10), 671-680.
[http://dx.doi.org/10.1016/S2468-1253(18)30233-4 ] [PMID:  30056030] 
[160] 
Mease, P.J.; Kellner, H.; Morita, A.; Kivitz, A.J.; Papp, K.A.; Aslanyan, S.; Berner, B.; Chen, K.; Eldred, A.; Behrens, F.  Efficacy and safety results from a phase 2 trial of risankizumab, a selective IL-23p19 inhibitor, in patients with active psoriatic arthritis ACR/ARHP Annual Meeting, 2017.
[161] 
Mease, P.J.; Kellner, H.; Morita, A.; Kivitz, A.J.; Papp, K.A.; Aslanyan, S.; Berner, B.; Chen, S.; Eldred, A.; Behrens, F. OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: Results from a phase 2 trial. Ann. Rheum. Dis.,  2018, 77, 200-201.
[162] 
Banaszczyk, K. Risankizumab in the treatment of psoriasis - literature review. Reumatologia,  2019, 57(3), 158-162.
[http://dx.doi.org/10.5114/reum.2019.86426 PMID: 31462831] 
[163] 
Zaba, L.C.; Suárez-Fariñas, M.; Fuentes-Duculan, J.; Nograles, K.E.; Guttman-Yassky, E.; Cardinale, I.; Lowes, M.A.; Krueger, J.G. Effective treatment of psoriasis with etanercept is linked to sup- pression of IL-17 signaling, not immediate response TNF genes. J. Allergy Clin. Immunol.,  2009, 124, 1022-10.
[164] 
Banno, T.; Gazel, A.; Blumenberg, M. Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J. Biol. Chem.,  2004, 279(31), 32633-32642.
[http://dx.doi.org/10.1074/jbc.M400642200 PMID: 15145954] 
[165] 
Campanati, A.; Molinelli, E.; Brisigotti, V.; Offidani, A. Biologic Therapy in Psoriasis (Part I): Efficacy and safety of tumor necrosis factor- α inhibitors. Curr. Pharm. Biotechnol.,  2017, 18(12), 945-963.
[http://dx.doi.org/10.2174/1389201019666180209121804 ] [PMID:  29424306] 
[166] 
Campanati, A.; Benfaremo, D.; Luchetti, M.M.; Ganzetti, G.; Gabrielli, A.; Offidani, A. Certolizumab pegol for the treatment of psoriasis. Expert Opin. Biol. Ther.,  2017, 17(3), 387-394.
[http://dx.doi.org/10.1080/14712598.2017.1283401 ] [PMID:  28165828] 
[167] 
Luchetti, M.M.; Benfaremo, D.; Campanati, A.; Molinelli, E.; Ciferri, M.; Cataldi, S.; Capeci, W.; Di Carlo, M.; Offidani, A.M.; Salaffi, F.; Gabrielli, A. Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: Two-year clinical experience of a dermo-rheumatologic clinic. Clin. Rheumatol.,  2018, 37(10), 2741-2749.
[http://dx.doi.org/10.1007/s10067-018-4238-4 PMID: 30056525] 
[168] 
Carrascosa, J.M.; van Doorn, M.B.; Lahfa, M.; Nestle, F.O.; Jullien, D.; Prinz, J.C. Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies. J. Eur. Acad. Dermatol. Venereol.,  2014, 28(11), 1424-1430.
[http://dx.doi.org/10.1111/jdv.12549 PMID: 24841895] 
[169] 
Warren, R.B.; Smith, C.H.; Yiu, Z.Z.N.; Ashcroft, D.M.; Barker, J.N.W.N.; Burden, A.D.; Lunt, M.; McElhone, K.; Ormerod, A.D.; Owen, C.M.; Reynolds, N.J.; Griffiths, C.E.M. Differential drug survival of biologic therapies for the treatment of psoriasis: A prospective observational cohort study from the british association of dermatologists biologic interventions register (BADBIR). J. Invest. Dermatol.,  2015, 135(11), 2632-2640.
[http://dx.doi.org/10.1038/jid.2015.208 PMID: 26053050] 
[170] 
Campanati, A.; Ganzetti, G.; Giuliodori, K.; Molinelli, E.; Offidani, A. Biologic therapy in psoriasis: Safety profile. Curr. Drug Saf.,  2016, 11(1), 4-11.
[http://dx.doi.org/10.2174/1574886310666151014115532 ] [PMID:  26463245] 
[171] 
Gniadecki, R.; Bang, B.; Bryld, L.E.; Iversen, L.; Lasthein, S.; Skov, L. Comparison of long-term drug survival and safety of biologic agents in patients with Psoriasis vulgaris. Br. J. Dermatol.,  2015, 172(1), 244-252.
[http://dx.doi.org/10.1111/bjd.13343 PMID: 25132294] 
[172] 
De Simone, C.; Amerio, P.; Amoruso, G.; Bardazzi, F.; Campanati, A.; Conti, A.; Gisondi, P.; Gualdi, G.; Guarneri, C.; Leoni, L.; Loconsole, F.; Mazzotta, A.; Musumeci, M.L.; Piaserico, S.; Potenza, C.; Prestinari, F. Immunogenicity of anti-TNFα therapy in psoriasis: A clinical issue? Expert Opin. Biol. Ther.,  2013, 13(12), 1673-1682.
[http://dx.doi.org/10.1517/14712598.2013.848194 PMID: 24107126] 
[173] 
Johnston, A.; Guzman, A.M.; Swindell, W.R.; Wang, F.; Kang, S.; Gudjonsson, J.E. Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling. Br. J. Dermatol.,  2014, 171(1), 97-107.
[http://dx.doi.org/10.1111/bjd.12937 PMID: 24601997] 
[174] 
Lebwohl, M.G.; Blauvelt, A.; Menter, A.; Papp, K.A.; Guenthner, S.; Pillai, R.; Israel, R.J.; Jacobson, A. Efficacy, safety, and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with brodalumab for 5 years in a long-term, open-label, phase II study. Am. J. Clin. Dermatol.,  2019, 20(6), 863-871.
[http://dx.doi.org/10.1007/s40257-019-00466-2 PMID: 31493163] 
[175] 
Saunte, D.M.; Mrowietz, U.; Puig, L.; Zachariae, C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br. J. Dermatol.,  2017, 177(1), 47-62.
[http://dx.doi.org/10.1111/bjd.15015 PMID: 27580411] 
[176] 
Veldhoen, M. Interleukin 17 is a chief orchestrator of immunity. Nat. Immunol.,  2017, 18(6), 612-621.
[http://dx.doi.org/10.1038/ni.3742 PMID: 28518156] 
[177] 
O’Connor, W., Jr; Kamanaka, M.; Booth, C.J.; Town, T.; Nakae, S.; Iwakura, Y.; Kolls, J.K.; Flavell, R.A. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol.,  2009, 10(6), 603-609.
[http://dx.doi.org/10.1038/ni.1736 PMID: 19448631] 
[178] 
Marwaha, A.K.; Leung, N.J.; McMurchy, A.N.; Levings, M.K. TH17 cells in autoimmunity and immunodeficiency: Protective or pathogenic? Front. Immunol.,  2012, 3, 129.
[http://dx.doi.org/10.3389/fimmu.2012.00129 PMID: 22675324] 
[179] 
Li, L.; Boussiotis, V.A. The role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory bowel disease and colon cancer. Clin. Immunol.,  2013, 148(2), 246-253.
[http://dx.doi.org/10.1016/j.clim.2013.05.003 PMID: 23773923] 
[180] 
Kashani, A.; Schwartz, D.A. The expanding role of Anti-IL-12 and/or Anti-IL-23 antibodies in the treatment of inflammatory bowel disease. Gastroenterol. Hepatol., (N. Y.),  2019, 15(5), 255-265.
[PMID: 31360139] 
[181] 
Pithadia, D.J.; Reynolds, K.A.; Lee, E.B.; Liao, W.; Wu, J.J. Tildrakizumab in the treatment of psoriasis: Latest evidence and place in therapy. Ther. Adv. Chronic Dis.,  2019, 10, •••.https://journals.sagepub.com/doi/10.1177/2040622319865658
[PMID:  31448070] 
[182] 
Witjes, H.; Khatri, A.; Diderichsen, P.M.; Mandema, J.; Othman, A.A. Meta-analyses of clinical efficacy of risankizumab and adalimumab in chronic plaque psoriasis: Supporting evidence of risankizumab superiority. Clin. Pharmacol. Ther.,  2020, 107(2), 435-442.
[http://dx.doi.org/10.1002/cpt.1624 PMID: 31502263] 
[183] 
Molinelli, E.; Campanati, A.; Brisigotti, V.; Offidani, A. biologic therapy in psoriasis (Part II): Efficacy and safety of new treatment targeting IL23/IL-17 pathways. Curr. Pharm. Biotechnol., 2017, 18(12), 964-978.
[http://dx.doi.org/10.2174/1389201019666180103140643] [PMID: 29299984] 
Cite As
Current Pharmaceutical Biotechnology

Novel Therapeutic Approaches and Targets for Treatment of Psoriasis

Abstract

Graphical Abstract
